USFDAJun 29, 2026, 04:06 PM
Gain Therapeutics Receives FDA IND Authorization for GT-02287
AI Summary
Gain Therapeutics announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application for GT-02287. This authorization paves the way for the initiation of the Company's Phase 2 clinical development of GT-02287 for Parkinson's disease in the U.S., expected during 3Q26. The FDA's decision follows positive Phase 1 results demonstrating both biomarker and clinical evidence of activity with favorable safety and tolerability.
Key Highlights
- FDA authorized IND application for GT-02287 for Parkinson's disease.
- Phase 2 clinical development in the U.S. expected to begin in 3Q26.
- Phase 1 results showed favorable safety and tolerability for GT-02287.
- Biomarker analysis showed an average 81% reduction in CSF GluSph after 90 days.
- Clinical findings included improvements in MDS-UPDRS Part II and III scores.
- GT-02287 is the first allosteric modulator from Gain's Magellan™ AI platform to receive IND clearance.
- Parkinson's disease affects over 1.1 million people in the United States.
Price Impact
More from GANX